Adverse Events After the Third Dose of COVID-19 Vaccine: A Case Study of Healthcare Workers at Buntharik Hospital, Thailand
Article Sidebar
Main Article Content
Abstract
ABSTRACT
Introduction: COVID-19 vaccine is currently being developed then the information regarding the unfavorable adverse events of vaccines is not clearly known.
Objective: The purpose of this study was to estimate the prevalence of and to determine factor adverse events after receiving the third dose of COVID-19 vaccine among healthcare workers who were working at Buntharik hospital in Ubon Ratchathani Province.
Methods: A cross-sectional study was conducted for data collection among healthcare workers who received the third dose of the AstraZeneca vaccine in July 2021. Data were collected from LINE group which was specific design to monitor the adverse events following immunization (AEFI) among people who received the 3rddose of the COVID-19 vaccine. Independent t-test and logistic regression were used to detect mean differences and factors associated between variables at the significance level of a=0.05.
Results: A total of 74 participants were recruited into the study; 21.6% of vaccine-related adverse events without any severe symptoms were reported. More than half were females (62.2%), an average age was 37.2±10.5 years, and 18.8% were presented with chronic illness at the time of immunization. Fever was reported as the highest adverse event after getting the 3rddose (81.3%), myalgia (75.0%), and pain and edema at the injection site (56.3%). Two variables were found to be associated with having adverse events after getting the 3rddose of COVID-19 vaccination. Those who had body mass index (BMI) ³23 kg/m2 had a 5.3 time (95%CI=1.34-20.95) greater chance to have adverse events than those who were normal BMI. Those who received the 3rddose after the 2ndfor 56 days had a 3.4 time (95%CI=1.02-11.49) greater chance to have an adverse event than those who received their 3rddose after 28-41days of the 2nddose.
Conclusion: Individuals’ BMI and time interval between the 2nddose and 3rddose are presented as factors associated with presenting adverse event who receive COVID-19 vaccine. All people who are planning to receive COVID-19 vaccine should be informed in concerning their BMI and time between the doses to avoid adverse events.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
JHSAM publishes all articles in full open access, meaning unlimited use and reuse of articles with appropriate credit to the authors.
All our articles are published under a Creative Commons "CC-BY-NC-ND 4.0". License which permits use, distribution and reproduction in any medium,
provided that the original work is properly cited and is used for noncommercial purposes.
References
World Health Organization (WHO). WHO Coronavirus disease (COVID-19) Dashboard. Available from: https://covid19.who.int/
Department of Disease Control. Ministry of Public Health. COVID-19 Situation Report. Available from: https://ddc.moph.go.th/covid19-dashboard/
World Health Organization. Coronavirus disease (COVID-19): vaccines. Available from: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines
Department of Disease Control. Ministry of Public Health. Guidelines for COVID-19 Vaccination in Thailand's 2021 Epidemic Situation, June 2021. Available from: https://tmc.or.th/covid19/download/pdf/covid-19-public-Vaccine-040664.pdf
Department of Disease Control. Ministry of Public Health. Guidelines for COVID-19 Vaccination in Thailand's 2021 Epidemic Situation, 2nd Edition, August 2021. Available from: https://ddc.moph.go.th/vaccine-covid19/getFiles/11/1628849610213.pdf
Department of Disease Control. Ministry of Public Health. Guidelines for Vaccination Against COVID-19 Epidemic in Thailand 2021. Available from: https://cvp1.moph.go.th
Wanvimonsuk K, Thianthong S, Gojaseni P. Comparing Humoral Response and Safety after Third Dose of SARS-CoV-2 Vaccines in Healthcare Workers Who Received 2 Doses of CoronaVac. Royal Thai Air Forces Medical Gazzette. 2022: 68(1): 1-9.
Pinpathomrat N, Intapiboon P, Seepathomnarong P, Ongarj J, Sophonmanee R, Hengprakop J, et al. Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population. Npj Vaccines 2022;7(52). Doi: 10.1038/s41541-022-00475-z.
Leechanavanichpan P, Tunlayadechanont P, Sriudomporn N, Setthaudom C, Maude R, Osiri S. Immunogenicity and adverse effects of the third booster dose with ChAdOx1 among dental care workers after receiving a full dose of CoronaVac. M Dent J [Internet]. 2022 [cited 2022 Dec 27];42(2):77-88. Available from: https://he02.tci-thaijo.org/index.php/mdentjournal/article/view/257157/175960
Hidayat R, Mustika AP, Avisha F, Djuliannisaa Z, Winari DD, Putri RA, et al. Surveillance of Adverse Events Following Immunization (AEFI) after Third Dose Booster Vaccination with mRNA-Based Vaccine in Universitas Indonesia Hospital Health Personnel. Vaccines. 2022: 10(6): 877-887.
Kanokudom S, Assawakosri S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, et al. Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine. Vaccines [Internet]. 2022 [cited 2022 Dec 27]; 10:86. Available from: https://www.mdpi.com/2076-393X/10/1/86